Abstract
Abstract
Background
We evaluated the long-term cost-effectiveness of antihypertensive traditional Chinese medicines (TCMs) and to compare the cost-effectiveness of a combined treatment consisting of compound Apocynum tablets and Nifedipine sustained-release tablets with the cost-effectiveness of treatment with Nifedipine sustained-release tablets alone.
Methods
A Markov model was used to simulate the potential incremental cost-effectiveness per quality-adjusted life year (QALY) to be gained from compound Apocynum tablets and Nifedipine sustained-release tablets compared with Nifedipine sustained-release tablets alone. Model parameter estimates were informed by previously published studies. The direct medical costs of outpatients with hypertension were estimated from the health care provider’s perspective. A 5% annual discount rate was applied to both costs and QALYs.
Results
TCMs combined with Nifedipine sustained-release tablets group generated a total 20-year cost of 11,517.94 RMB (US $1739.87), whereas Nifedipine sustained-release tablets alone group resulted in a 20-year cost of 7253.71 RMB (US $1095.73). TCMs combined with Nifedipine sustained-release tablets group resulted in a generation of 12.69 QALYs, whereas Nifedipine sustained-release tablets alone group resulted in 12.50. The incremental cost-utility ratio was 22,443.32 RMB (US $3390.23) per QALY. Considering the threshold of 1 GDP per capita in China in 2018 (US $9764.95), the combination of compound Apocynum tablets and Nifedipine sustained-release tablets was a cost-effective strategy. One-way and probabilistic sensitivity analysis showed unchanged results over an acceptable range.
Conclusions
Combining Traditional Chinese Medicines with chemical medicines is more cost-effective strategy in the treatment of hypertension.
Funder
National Key R&D Program of China
Sichuan Administration of Traditional Chinese Medicine
the 111 Project
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine
Reference47 articles.
1. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the global burden of disease study 2010. Lancet. 2013;381(9882):1987–2015.
2. Hua Q, Fan L, Li J, et al. China experts consensus on the managements of hypertension in the very old people. Chin J Cardiovasc Med. 2015;06:401–9.
https://doi.org/10.3969/j.issn.1007-5410.2015.06.001
.
3. Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res. 2016;16:175.
4. Hua SH, Liu GE, Sun LH, et al. The effect of overweight and obesity on the burden of medical expenses in patients with hypertension. Health Econ Res. 2017;10:27–9.
5. Yikona JI, Wallis EJ, Ramsay LE, et al. Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. J Hypertens. 2002;20(11):2173–82.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献